ImmunityBio, Inc. (IBRX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en San Diego, CA, United States. El CEO actual es Richard Gerald Adcock.
IBRX tiene fecha de IPO 2015-07-28, 671 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $7.81B.
ImmunityBio, Inc. is a clinical-stage biotechnology company headquartered in San Diego that develops immunotherapies and vaccines for cancer and infectious diseases. The company's pipeline includes advanced immunotherapy and cell therapy platforms, featuring antibody-cytokine fusion proteins, synthetic immunomodulators, natural killer cells, and T cell therapies, with multiple candidates in Phase II and III clinical trials for liquid and solid tumors such as bladder, pancreatic, and lung cancers, as well as viral pathogens including SARS-CoV-2 and HIV. ImmunityBio has established strategic partnerships with leading research institutions including the National Cancer Institute and collaboration or licensing agreements with multiple biotechnology and healthcare organizations to advance its therapeutic pipeline.
